Navigation Links
Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
Date:1/23/2013

SAN DIEGO, Jan. 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2) NBI-98854.

European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. This patent covers chemical compositions, pharmaceutical compositions and uses of various compounds including our Phase IIb clinical candidate NBI-98854.

In addition to the already issued composition of matter patent, the United States Patent and Trademark Office recently granted a second patent for NBI-98854. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027. This patent is in addition to the previously issued United States Patent Number 8,039,627 which covers the NBI-98854 composition and expires in late 2029.

"We are very pleased to receive this composition of matter patent from the European Patent Office," said Kevin C. Gorman , Chief Executive Officer of Neurocrine Biosciences. "This EU patent, coupled with our new United States methods of use patent, and the existing United States composition of matter patent provide a strong intellectual property estate around NBI-98854. We intend to continue to expand our VMAT2 patent footprint on NBI-98854 and our other VMAT2 inhibitors in early development."

About NBI-98854

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines or other receptors thereby reducing the likelihood of "off target" side effects.  NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may also be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and tardive dystonia.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2011 and on Form 10-Q for the quarter ended September 30, 2012. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
2. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
4. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
6. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
10. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
11. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
Breaking Medicine Technology:
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 , ... ... has settled over 175,000 debt accounts, translating to in excess of $835 million in ... card debt and other unsecured loans are some of the categories of debt settled ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, ... light filter. When we’re born, Nature gives us a full supply of melanin ... age, we continuously lose this natural glare-reducing pigment; however, around the age of thirty, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets a ... by Xlibris on July of 2014). This book details the recent advances and techniques ... that benefit people who have lost all of their natural teeth . , ...
(Date:9/19/2017)... Pendleton, California (PRWEB) , ... September 19, 2017 , ... ... members and their families, announces the release of a series of videos and a ... epidemic for service members in the United States as part of its ongoing mission. ...
Breaking Medicine News(10 mins):